Marker Therapeutics up on EMA's 'orphan drug' tag for blood cancer therapy

Marker Therapeutics

10/07/2023 14:11

** Shares of cancer immunotherapy developer Marker
Therapeutics Inc  MRKR.O  rise 4.8% to $4.6 before the bell
    ** Company says European Medicines Agency (EMA) granted
"orphan drug" designation to its experimental therapy, MT-401,
to treat patients with acute myeloid leukemia (AML)
    ** AML is a type of cancer in which the bone marrow makes a
large number of abnormal blood cells
    ** EMA's orphan designation is assigned to a medicine
intended for use against a life-threatening or chronically
debilitating condition that affect fewer than five in 10,000
persons in the European Union
    ** MT-401 already has "orphan drug" tag from U.S. FDA for
treatment of AML after stem cell transplant
    ** As of last close, stock up 63.22% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))